Physician profile
Stephen Hess
NPI 1033279955
$1,700,572.42
in general payments reported to CMS, 2019-2025
42 companies · $296K in 2025
The $296K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185K · 2020: $92K · 2021: $147K · 2022: $201K · 2023: $314K · 2024: $466K · 2025: $296K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $809K · Travel and Lodging: $129K · Consulting Fee: $67K · Food and Beverage: $34K · Honoraria: $23K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $808,907.50 |
| Travel and Lodging | $129,413.89 |
| Consulting Fee | $67,382.12 |
| Food and Beverage | $34,374.40 |
| Honoraria | $22,830.87 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,760.00 |
| Education | $296.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $245,232.64 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $169,480.10 | 2019-2025 | Ilumya, Blu-U, Winlevi |
| Janssen Biotech, INC. | $159,119.64 | 2019-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $154,840.21 | 2019-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $142,192.77 | 2019-2024 | Tremfya |
| Abbvie INC. | $137,498.40 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $125,508.50 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $89,505.94 | 2021-2025 | Sotyktu |
| Ucb, INC. | $76,992.66 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $68,957.88 | 2019-2025 | |
| Genzyme Corporation | $66,533.76 | 2019-2025 | |
| Dermavant Sciences, INC. | $49,430.61 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $38,391.88 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Arcutis Biotherapeutics, INC. | $32,235.91 | 2023-2025 | Zoryve |
| Incyte Corporation | $30,193.29 | 2020-2025 | Opzelura |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.